Marshall Wace
ABUS icon

Marshall Wace’s Arbutus Biopharma ABUS Stock Holding History

Marshall Wace’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-392,932
Closed -$751K – 2877
2022
Q3 		$751K Buy
+392,932
New +$925K ﹤0.01% 2547
2021
Q4 		– Sell
-397,088
Closed -$1.7M – 3810
2021
Q3 		$1.7M Buy
+397,088
New +$1.32M 0.01% 1668

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace's ABUS Position: Q4 2022 in Review

Marshall Wace sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 392,932 shares — an estimated $751K sold.

Marshall Wace first reported a position in ABUS in Q3 2021 and held it in 2 quarters. The position peaked at $1.7M in Q3 2021. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

  • Marshall Wace reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
  • Marshall Wace sold 392,932 Arbutus Biopharma shares in Q4 2022, an estimated $751K.
  • Marshall Wace first reported a position in Arbutus Biopharma in Q3 2021 and held it in 2 quarters.
  • Marshall Wace's Arbutus Biopharma position peaked at $1.7M in Q3 2021.
  • 114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.